RichardT.SilverMD

Oncology • New York, NY

Hematologic Oncology

Professor, Medicine, Weill Cornell Medical College

Join to view full profile

Dr. Silver is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Silver's full profile

Already have an account?

Office
520 E 70th St
# Starr
New York, NY 10021
Phone+1 646-962-2700

Fax+1 646-962-0115

Education & Training

New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1956 - 1958
New York Presbyterian Hospital (Cornell Campus)Internship, Internal Medicine, 1953 - 1954
Weill Cornell MedicineClass of 1953

Certifications & Licensure

NY State Medical License 1954 - 2025
PA State Medical License 1983 - 1984
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Familial Myeloproliferative Disorders Start of enrollment: 2008 Mar 01
Completed
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Start of enrollment: 2011 Sep 01
Completed
Phase 2
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Start of enrollment: 2011 Sep 01
Completed
Phase 3
Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis Start of enrollment: 2013 Jan 01
Terminated
Phase 2
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML Start of enrollment: 2014 Feb 01
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Transplant Outcomes in Myelofibrosis: Impact of Donor Type (Cord Blood Grafts Supported by CD34+ selected Cells [Haplo-Cord] Versus Matched Donors).
Nima Ghalehsari, Franco Castillo Tokumori, Zhengming Chen, Marie Liu, Sebastian A Mayer
Transplantation and Cellular Therapy. 2024-11-01
A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofi...
Ghaith Abu-Zeinah, Albert Qin, Harinder Gill, Norio Komatsu, John Mascarenhas
Annals of Hematology. 2024-09-01
1 citations
Are thrombosis, progression, and survival in ET predictable?
Ghaith Abu-Zeinah, Katie Erdos, Neville Lee, Ahamed Lebbe, Imane Bouhali
Blood Cancer Journal. 2024-06-25

Abstracts/Posters

Recombinant Interferon-_ Reduces Thrombotic Events in Patients with Polycythemia Vera
Richard T. Silver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Set...
Richard T. Silver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia
Richard T. Silver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival
Richard T. Silver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group
Richard T. Silver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermedi...
Richard T. Silver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolit...
Richard T. Silver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Press Mentions

Dave Boule Confronted Polycythemia Vera with an Accountant’s ConsistencyJune 17th, 2022
Cancer Pill Could Keep Patients Alive for More Than 10 Years, New Study FindsMarch 10th, 2017
'Imatinib Changed Everything'March 8th, 2017
Join now to see all